Samuel Kintz Sells 47,709 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN) CEO Samuel Kintz sold 47,709 shares of the firm’s stock in a transaction that occurred on Thursday, April 11th. The stock was sold at an average price of $25.04, for a total transaction of $1,194,633.36. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Samuel Kintz also recently made the following trade(s):

• On Monday, March 25th, Samuel Kintz sold 12,000 shares of Enliven Therapeutics stock. The shares were sold at an average price of $17.56, for a total value of $210,720.00.
• On Thursday, January 25th, Samuel Kintz sold 12,000 shares of Enliven Therapeutics stock. The shares were sold at an average price of $15.69, for a total value of $188,280.00.

Enliven Therapeutics Price Performance

Shares of NASDAQ ELVN traded down $1.14 during mid-day trading on Monday, reaching $19.94. 745,161 shares of the company’s stock were exchanged, compared to its average volume of 218,023. The firm has a market capitalization of $821.53 million, a price-to-earnings ratio of -9.03 and a beta of 1.06. Enliven Therapeutics, Inc. has a 52 week low of $9.80 and a 52 week high of $26.00. The firm has a 50-day moving average price of $16.77 and a two-hundred day moving average price of $14.21.

Enliven Therapeutics (NASDAQ:ELVN) last announced its quarterly earnings data on Thursday, March 14th. The company reported ($0.47) earnings per share for the quarter, topping the consensus estimate of ($0.56) by $0.09. As a group, sell-side analysts forecast that Enliven Therapeutics, Inc. will post -2.16 EPS for the current fiscal year.

Institutional Investors Weigh In On Enliven Therapeutics

Several large investors have recently added to or reduced their stakes in the company. AJOVista LLC purchased a new position in Enliven Therapeutics during the 4th quarter valued at about $28,000. Tower Research Capital LLC TRC purchased a new position in Enliven Therapeutics during the 1st quarter valued at about $36,000. Ameritas Investment Partners Inc. purchased a new position in Enliven Therapeutics during the 2nd quarter valued at about $39,000. Royal Bank of Canada grew its holdings in shares of Enliven Therapeutics by 532.7% during the second quarter. Royal Bank of Canada now owns 3,075 shares of the company’s stock worth $63,000 after purchasing an additional 2,589 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. purchased a new position in shares of Enliven Therapeutics during the fourth quarter worth about $66,000. Hedge funds and other institutional investors own 95.08% of the company’s stock.

Analyst Ratings Changes

Separately, Mizuho began coverage on Enliven Therapeutics in a research note on Tuesday, April 9th. They set a “buy” rating and a $34.00 target price on the stock.

About Enliven Therapeutics

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.